Navigation Links
Serial Monitoring With ImmuKnow(R) is Useful in the Risk Assessment of Kidney Transplant Recipients
Date:5/30/2009

The results of this study will be presented during the American Transplant Congress in Boston, MA May 30 - June 3, 2009

COLUMBIA, Md., May 30 /PRNewswire/ -- Lead investigator, Dr. Manuel R. Carreno, along with his colleagues from the University of Miami, evaluated whether single or serial ImmuKnow assessments are most useful in determining rejection or infection in kidney transplant recipients. Patients were randomly selected after 30-60 days (N=134) or 335-395 days posttransplant (N=91) and tested with ImmuKnow.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090424/NE99362LOGO )

Based on the results of this study, Dr. Carreno commented, "Pre-transplant baseline readings and serial monitoring with ImmuKnow are crucial for posttransplant risk assessments. Our results suggest that an isolated ImmuKnow test is insufficient to aid in the management of posttransplant recipients." In addition, Dr. Carreno said, "Serial posttransplant ImmuKnow values are useful because patients with 'immunological quiescence' have fewer complications compared to patients with erratic ImmuKnow values."

"We believe that ImmuKnow is a valuable, noninvasive tool for helping clinicians manage their transplant patients," added Dr. Phillip Ruiz, author and Medical Director of the Transplant Laboratories. "We recognize that the immune system responds quickly to change and that regular patient monitoring is critical to understanding these changes, which is why we test weekly in the first month posttransplant, followed by weeks 6 and 8 testing in the second month, monthly testing during months 3-12, and then as needed when circumstances suggest the immune function is affected."

Risk assessment was performed within 3 stud
'/>"/>

SOURCE Cylex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
4. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
5. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
8. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
9. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
11. CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinsons Disease Motor Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... 31, 2015 , ... Regulatory agencies have acknowledged impurities especially ... process. Thus, innovator companies must understand what will be needed in the drug ... been hosting multiple educational panels and seminars for experts to share advice concerning ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Food ... food and beverage processors, equipment manufacturers and leaders in the field of academia. ... weighing and formulation for manufacturers of bakery and snacks; beverages; dairy; meat, poultry ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for ... first commercially available new FDA approved system in the last 14 years, and the ... high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, ...
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a finalist for ... High Tech Awards. , Now in its 22nd year, this premier awards event celebrates ... across the nation and around the world. The OC Tech Alliance will announce all ...
Breaking Biology Technology:Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4
... is Superior to Placebo, Similar Efficacy to ... a Day, and Less Daytime Drowsiness, ... (Nasdaq:,CEPH) announced the pooled analysis of two ... (cyclobenzaprine,hydrochloride extended-release capsules), a new once-daily extended-release,skeletal ...
... Quantitative Research ... Worldwide, NEW YORK, ... of those fielded in the US and abroad -- were,conducted online last ... report, released today, indicates that Internet-based market,research -- once the orphan of ...
... Inc. (Nasdaq: ONXX ) today announced that it ... and full year 2007,financial results and provide a business ... Time (2:00 p.m. Pacific Time). Financial results,for the fourth ... released,earlier that day., Interested parties may access a ...
Cached Biology Technology:Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting 2Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting 3Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting 4Technology Transforms Market Research in Pharmaceutical Industry 2Technology Transforms Market Research in Pharmaceutical Industry 3Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast 2
(Date:8/28/2015)... August 28, 2015 According to ... Market by Assessment Type (Pen & Paper Based, Hosted, ... Corporate Learning, Academic Research), Vertical and Region - Global ... Training Market to grow from USD 2.4 Billion in ... Compound Annual Growth Rate (CAGR) of 25.6% from 2015 ...
(Date:8/26/2015)... , August 26, 2015 ... Four, and Five Factor), Application (Travel & Immigration, Government, ... - Global Forecast to 2020", published by MarketsandMarkets, Multi-Factor ... by 2020, growing at a CAGR of 17.7% between ... and 82 F igures spread through 169 ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
... tempers the killing activity of a specific group of immune ... attack tumor cells and cells infected by viruses. The key ... which has been known for a long time and which ... Dr. Armin Rehm together with immunologist Dr. Uta Hpken of ...
... cause plants to store GM proteins in special ,protein ... increasing the overall protein yield. Researchers writing in the ... the mechanism by which the synthetic biopolymer increases the ... a team of researchers from Agriculture and Agri-Food Canada ...
... Heidelberg, Germany, 6 August 2009 The European ... a new private pension plan for EMBO Fellows. The ... needs of highly mobile scientists. Post-doctoral researchers who ... enrolling in the pension plan from 1 January 2010. ...
Cached Biology News:Estrogen-dependent switch tempers killing activity of immune cells 2EMBO pioneers pension plan for internationally mobile postdoctoral researchers 2EMBO pioneers pension plan for internationally mobile postdoctoral researchers 3